account_id none on file
legal_name Climb Bio, Inc.
ticker CLYM
cik 1768446
domain climbbio.com
linkedin_company_url https://www.linkedin.com/company/climbbio/
entry_point_account_id none on file
name Climb Bio Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 10 executives 2 family 0
why_nownone on file
callsnone on file
filings
The increase was primarily due to higher personnel-related expenses of $1.5 million, including increased stock-based compensation of $0.7 million, driven by increased headcount.
filing / Aug 6, 2026 / receipt
The increase was primarily due to higher personnel-related expenses of $1.8 million, including increased stock-based compensation of $0.6 million, driven by increased headcount.
filing / Aug 6, 2026 / receipt
Our business strategy incorporates potential international expansion as we seek to conduct clinical trials, obtain regulatory approval for, and commercialize, our product candidates in patient populations outside the U.S.
filing / Aug 6, 2026 / receipt
Any of these factors could harm our future international expansion and operations and, consequently, our results of operations.
filing / Aug 6, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.
filing / Aug 6, 2026 / receipt
Personnel-related expenses increased by $0.6 million due primarily to increased headcount, partially offset by a decrease in stock-based compensation expenses of $0.3 million.
filing / May 7, 2026 / receipt
The increase was due primarily to higher personnel-related expenses of $0.3 million from increased headcount and higher consulting fees of $0.1 million, partially offset by a decrease in legal fees of $0.3 million.
filing / May 7, 2026 / receipt
Our business strategy incorporates potential international expansion as we seek to conduct clinical trials, obtain regulatory approval for, and commercialize, our product candidates in patient populations outside the U.S.
filing / May 7, 2026 / receipt
Any of these factors could harm our future international expansion and operations and, consequently, our results of operations.
filing / May 7, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.
filing / May 7, 2026 / receipt
executives
| Aoife Brennan | President and Chief Executive Officer | - | receipt |
| Cindy Driscoll | Senior Vice President | - | receipt |
familynone on file
upcoming
| 2026-11-05 | earnings call | scheduled | ir |
changes
| 2025-06-18 | Senior Vice President, appointed | sec_8k |
| 2024-08-27 | Executive Chairman, departed | sec_8k |
| 2024-06-12 | President and Chief Executive Officer, appointed | sec_8k |
mcp_package_hint
slug climb-bio-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$